GlassScriptPhysician profile
Chandra Reddy Polam
NPI 1871552232
$8,005.39
in general payments reported to CMS, 2019-2025
39 companies · $910 in 2025
The $910 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $854 · 2021: $1,271 · 2022: $1,229 · 2023: $1,271 · 2024: $1,135 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,435.69 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $915.59 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $822.16 | 2019-2025 | Repatha, Otezla, Tezspire |
| Merck Sharp & Dohme LLC | $603.80 | 2021-2025 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.53 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $559.54 | 2019-2025 | |
| Daiichi Sankyo INC. | $448.15 | 2019-2025 | Injectafer, Vanflyta |
| Bayer Healthcare Pharmaceuticals INC. | $389.28 | 2022-2025 | |
| Amarin Pharma, INC. | $355.40 | 2019-2022 | |
| Novo Nordisk INC | $297.98 | 2019-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $297.12 | 2019-2024 | Eliquis, Camzyos |
| Lilly USA, LLC | $188.09 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $93.65 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $92.05 | 2024-2025 | Voquezna |
| Dexcom, INC. | $91.71 | 2023-2025 | Dexcom G6 Transmitter |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Polam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.